Rigel to Present at Keystone Symposia Conference
Presentation Date: Sunday, January 25, 2009
Time: 2:30 - 4:30pm
Session: Workshop 2: New Therapeutic Approaches to MS
Presentation Title: The orally bioavailable Protein Kinase C InhibitorRGE-80 can abrogate EAE disease induction and ameliorates disease in atherapeutic setting
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our pioneering research focuses on intracellular signaling pathwaysand related targets that are critical to disease mechanisms. Rigel'sproductivity has resulted in strategic collaborations with largepharmaceutical partners to develop and market our product candidates. Rigelhas product development programs in inflammatory/autoimmune diseases such asrheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Contact: Raul Rodriguez
SOURCE Rigel Pharmaceuticals, Inc.
You May Also Like